Wound Care Technologies: Sales Growth, Change, Global Forecast

MedMarket Diligence is hours away from publishing its 2015 report on the worldwide wound management market.

The report is entitled, “Worldwide Wound Management, Forecast to 2024: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”. The report is described in detail at link.

The very diverse field that is wound management encompasses technologies from gauze to bioengineered skin and skin substitutes and many in between. Growth rates range from flat to over 15% annually through 2024.

Source: MedMarket Diligence, LLC; Report #S251.

The highest growth segments in medical technology sectors typically derive their high growth from modest absolute changes on very small volume and therefore rarely can sustain that growth over time. However, in wound management, the use of bioengineered skin and skin substitutes will result in the highest cumulative sales compared to all segments from 2015 to 2024 — excluding, that is, the high volume segments of traditional adhesives, gauzes, and non-adherent dressings.  Also noteworthy is the second highest cumulative sales over this period was for antimicrobial dressings, despite this segment having relatively modest growth on a percentage basis, but proceeding from significant sales in 2015 (already at over $1.5 billion).

Source: MedMarket Diligence, LLC; Report #S251.

During the forecast period, the most significant change evident in sales is the jump in the share of the market represented by bioengineered and other skin replacements, as noted above. But with compound annual growth rates (to 2024) in sales in the different wound segments ranging from near 1% to nearly 20% — for segments with 2015 sales at a low of $300 million and a high of $15 billion — there is considerable shifting of shares of the global wound market.

Source: MedMarket Diligence, LLC; Report #S251.

On a geographic basis, wound care technology migration, efforts to secure underserved patient caseload, and other forces result in growth rates that vary by country or region. The well-developed USA market therefore does not compare in uptake of both old and new technologies within growth markets like China and others in the Asia/Pacific region.

Source: MedMarket Diligence, LLC; Report #S251.

Wound management: Novel technologies, high growth, high volume, MANY companies

Wound management technologies span an incredible spectrum of technologies — bandages, tapes, dressings (bioactive, antimicrobial, non-adherent…), sutures, staples, bioengineered skin & substitutes, negative pressure, ultrasound, pulsed electromagnetic therapy, growth factors, gene therapy…

Wound management is an old medical practice, and wounds have not changed in nature other than the mix prevalence of different wound types. Yet, the volume of all wounds, and the need to improve they may be managed, support development of many new technology and changes in clinical practice. In turn, this drives and sustains an unusually large number of competitors.

Source: MedMarket Diligence, LLC; Report #S251.

 

Below is a list, drawn from the forthcoming December 2015 report (#S251) from MedMarket Diligence global wound management market, of companies that are sufficiently large or active or noteworthy for us to have specifically profiled in our report. The true number of companies in wound (and detailed but not “profiled” in our report) is in the hundreds.

3M Health Care, ACell, Acelity L.P. Inc., AcryMed Inc., Agennix Incorporated, AGT Sciences Ltd, Alliqua Biomedical, AlloSource, Altrika Ltd, Amniox Medical, Inc., Anika Therapeutics, Argentum Medical, Avita Medical, B. Braun Melsungen AG, Biopharm GmbH, Biotime, Inc., Bio-Tissue, Inc., BSN medical, Cardium Therapeutics, CliniMed Limited, Coloplast Group, Covalon Technologies, Ltd., ConvaTec Inc., Cook Biotech, Inc., Covidien, Cytogenix, Cytomedix, Derma Sciences, Inc., DeRoyal Industries Inc., Devon Medical, Diapulse Corporation of America, Eqalix, Inc., E-QURE Corporation, Euroderm AG, Gentell Inc, Geritrex Corp., Hartmann Group, Hollister Incorporated, Imbed Biosciences, Inc., Integra LifeSciences, Inc., Kendall (Covidien), Kinetic Concepts, Inc. (KCI), Kuros Biosurgery AG, Laboratoires URGO, LifeCell Corporation, Lohmann & Rauscher International GmbH and Co. KG, Macrocure, Medline Industries, Microban International Ltd., MicroVas Technologies, Inc, MiMedx, Mölnlycke Health Care AB, NovaBay Pharmaceuticals, Oculus Innovative Sciences, Organogenesis Inc, Osiris Therapeutics, Perry Baromedical, Prospera, ReliaMed, RXi Pharmaceuticals, SafeBlood Technologies, Sanofi Biosurgery (formerly Genzyme Biosurgery), SANUWAVE Health, Inc., Shire Regenerative Medicine, Smith & Nephew plc, Sorbion GmbH & Co., KG, Soluble Solutions, LLC, Spiracur, Inc., Systagenix Wound Management (US), Inc., TEI Biosciences, Tissue Regeneration Technologies, LLC, Tissue Regenix Group plc., UDL Laboratories, Uluru, Inc., ViroMed Co., Ltd., Vomaris Innovations, Inc., Wound Management Technologies, Inc.

The MedMarket Diligence Report #S251, “Worldwide Wound Management, Forecast to 2024:
Established and Emerging Products, Technologies and Markets
in the Americas, Europe, Asia/Pacific and Rest of World” (see link for details), provides a current and forecast assessment (to 2024) of the worldwide market for wound management.

 

European market share analysis, interbody fusion devices, 2014

Screen Shot 2015-11-23 at 11.01.03 AM

Source: MedMarket Diligence, LLC; “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World” (Report #M540).

Growth in Treatment of Acute Stroke

Drawn from Report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019”, published by MedMarket Diligence, LLC.

Therapeutic management of stroke encompasses a broad scope of prophylactic, palliative and curative treatment modalities that are typically employed in some combinations during the preventive, acute and rehabilitation phases of stroke-related care delivery.

Historically, prevention has been universally regarded as the best form of medicine for dealing with any disease. This old wisdom is especially true in management of acute stroke, which represents a catastrophic event with a largely predetermined clinical progression and outcome that stem from the patient’s preexisting pathologies and can be only marginally altered with available emergent therapies.

The commonly accepted, current strategy of primary and secondary stroke prevention is focused on elimination or remedying of the modifiable risk factors that have been shown to create a general predisposition or directly contribute to the onset of acute cerebral ischemia or/and hemorrhage.

Within the context of general population, this strategy is targeting alleviation of certain lifestyle risk factors (such as smoking, obesity, physical inactivity, excessive alcohol consumption, drug abuse, high-fat diet etc.), which could contribute to the development of cardiovascular and other pathologies associated with increased propensity to stroke.

In patient caseloads with preexisting medical conditions (AFib, mechanical prosthetic valves, recent AMI, stoke or TIA, hypertension, diabetes, etc.) which are characterized by a high risk of adverse vascular events potentially leading to stroke, preventive strategy is focused on reducing such risks via a strict control and monitoring of corresponding hemostatic and hemodynamic parameters.

Finally, in persons with diagnosed cerebrovascular pathologies (high grade carotid stenosis, intracranial aneurysms and AVMs) the first line preventive therapy involves their repair or eradication, when technically possible.

The scope of FDA-approved medical and interventional modalities commonly employed in preventive management of stroke includes oral anticoagulation, antiplatelet, and lipid-lowering drug therapies, cerebral aneurysm and AVM repair surgery, carotid endarterectomy, stereotactic radiosurgery, as well as endovascular embolization of intracranial aneurysms and AVMs, carotid artery stenting with embolic protection, left atrial appendage closure, along with  rarely used and likely to be abandoned intracranial stenting.

In contrast to causes-oriented therapies used in stroke prevention, therapeutic modalities employed in the emergent management of acute stroke are focused almost exclusively on patients’ cardiopulmonary and hemodynamic support and ad hoc containment of dangerous complications and corresponding brain damage associated with stroke.

Among the life-threatening complications that commonly accompany acute cerebral hemorrhage or ischemia are cerebral edema; hydrocephalus; brain stem compression; vasospasm and pulmonary embolism.

Management of the aforementioned acute complications relies on a few proven treatment regimens, including (but not limited to):

  • medical therapy and catheter-based ventricular drainage of cerebrospinal fluid to control intracerebral pressure in patients at risk of edema, hydrocephalus or brain stem compression;
  • hypertensive hypervolemic hemodilution (or “triple-H” therapy) to treat ischemic neurological deficit from vasospasm following subarachnoid hemorrhage;
  • subcutaneous anticoagulation (with heparins or heparinoids) for prophylaxis of pulmonary embolism (which accounts for approximately 10% of deaths following stroke); and
  • elective hypothermia for temporary salvaging brain cells from necrosis due to hemorrhagic trauma or acute ischemia (although the latter technique has not been proven efficacious in clinical trials and was not endorsed in the latest, 2007 versions of the AHA hemorrhagic and ischemic stroke guidelines).

The currently available curative treatment options for acute stroke are limited to intravenous t-PA therapy (which has about 30% efficacy and is indicated for a very narrow cohort of eligible ischemic stroke patients only), investigational intra-arterial thrombolytic therapy, transcatheter cerebral thrombectomy (in patients who did not qualify for or failed t-PA therapy), and emergency craniotomy-based or endoscopic removal of stroke-related hematoma (which carries a 50% to 80% risk of mortality and is reserved for rapidly deteriorating young patients with large lobar hemorrhages).

Rehabilitation phase of stroke management relies on general physiotherapeutic techniques commonly used in patients with various physical and neurological disabilities. Prophylactics of recurrent cerebrovascular events in stroke survivors employs medical and interventional regimens referred to in the overview of primary and secondary stroke prevention.


Drawn from Report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019”, published by MedMarket Diligence, LLC.

 

The Competitive Landscapes of Spinal Fusion

In North America, the spine fusion market is dominated by Medtronic (Spinal and Biologics), followed by DePuy Synthes. The same goes for Western Europe.

However, the second, third, and lower tiers, which in aggregate represent hundreds of millions in sales annually each of North America and Europe, show a different competitive landscape, aside from the fact that both are also highly fragmented (see the numbers of smaller competitors who contribute in each case to the “Others” category).

Others includes: Wright Medical Technology, Medicrea, Graftys, Osteotech, Scient’x Groupe S.A., Exactech Spine, Biomatlante, Alphatec Spine, Bonovo Orthopedics, Inc, Spineart, Argomedical AG, Biedermann Motech GmbH & Co. KG, Biotech GmbH, Biotechni, Dieter Marquardt Medizintechnik GmbH, ESKA Implants AG, Gerraspine AG, Orthopaedic & Spine Development, Spinelab Ltd., Ulrich GmbH & Co.KG, Accel Spine, Apollo Spine as well as a large number of smaller start up companies based in North America (e.g. Advanced Spine Fixation Systems Inc) and a number of other smaller manufacturers based in Europe (e.g. Surgival-Grupo Cosias) and the Asia Pacific region (e.g. Sozhou Kangli (China).

Source: MedMarket Diligence, LLC; Report #M540, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021”.

 

Others includes: Wright Medical Technology, LDR Medical, K2M, Medicrea, Graftys, Osteotech, Exactech Spine, Biomatlante, Bonovo Orthopedics, Inc, Clariance Spine, Corin Cousin Biotech, Creaspine, OSD – Orthopaedic & Spine Development, SpineGuard, coLigne AG, Onur MEDiKAL San. Ve Tic Ltd. Sti., Spineart, Argomedical AG, Hipokrat Medical Devices Manufacturing and Marketing Inc., Inion Oy, Biedermann Motech GmbH & Co. KG, Biotech GmbH, Biotechni, Dieter Marquardt Medizintechnik GmbH, ESKA Implants AG, Gerraspine AG, Orthopaedic & Spine Development, Spinelab Ltd., Accel Spine, Apollo Spine as well as a large number of smaller start up companies based in Europe (e.g. Advanced Spine Fixation Systems Inc) and a number of other smaller manufacturers based in Europe (e.g. Vexim SAS) and the Asia Pacific region (e.g. Sozhou Kangli (China).

Source: MedMarket Diligence, LLC; Report #M540, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021”.

Growth in Neurointevention Procedure Volumes for Acute Stroke Treatment

The largest (39.8%) share of 2015 global therapeutic neurointerventional device revenues was generated in the U.S. market, followed by Western European marketplace with 32.3%, APAC markets with 18.5%, and the rest-of-the-world market segment with the remaining 9.4% of the global stroke-related neurointerventional system business.

During the forecast period, the overall worldwide volume of novel peripheral interventional and neurointerventional procedures and corresponding product sales are projected to experience a healthy growth expanding an average of 6.3% and 5.3% accordingly to over 308 thousand total interventions and $1,773.2 million in cumulative device revenues in the year 2019.

The largest absolute gains in the market can be expected in the biggest and most mature endovascular embolization system segment which is forecast to expand by $165 million to approximately $1,017 million in the year 2019.

The fastest relative advances are likely to occur in the smallest LAA closure and cerebral thrombectomy device segments which are expected to grow 16.3% and 10.1% to $121 million and $268.4 million in device revenues, respectively, in 2019.

Geography wise, underpenetrated APAC (particularly Chinese) marketplace is projected to register the fastest growth in stroke-related neuro-interventional market dollar volume, followed by the ROW market segment (albeit from a relatively low base), and highly mature U.S. and West European markets.

Source: MedMarket Diligence, LLC; Report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019.”

Cerebral Endovascular Embolization Cases, Procedures Growth

In 2014, endovascular embolization techniques were employed in approximately 90.5 thousand cerebral aneurysm and AVM repair procedures worldwide, of which aneurysm targeting interventions accounted for about 89.2%, with the rest contributed by AVMs hemoisolation.

During the forecast period, the total global volume of transcatheter neurovascular embolization procedures is projected to grow 4% per annum to an estimated 109.9 thousand interventions in the year 2019. The largest absolute and relative gains in cerebral embolization procedure volumes are expected in the largest Asian-Pacific states (mostly China) and the Rest-of-the-World, where low relative usage of endovascular techniques (30-35% versus 65-75% in the U.S. and Europe) will continue to support their increasing penetration of clinical practices and serve as the primary locomotive of growth in the corresponding global product market.

Largely mature U.S. and West European market geographies are likely to register considerably more modest advances in cerebral embolization procedure volumes.  Below is compared the growth rates to 2019 for cerebral endovascular embolization in the major Asia-Pacific countries (Japan, India, and China) to the same in Western Europe.

Screen Shot 2015-10-05 at 9.41.24 AM

Source: MedMarket Diligence, LLC; Report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019”.

 

Clinical procedure trends in the management of acute stroke

The scope of FDA-approved medical and interventional modalities commonly employed in preventive management of stroke includes oral anticoagulation, antiplatelet, and lipid-lowering drug therapies, cerebral aneurysm and AVM repair surgery, carotid endarterectomy, stereotactic radiosurgery, as well as endovascular embolization of intracranial aneurysms and AVMs, carotid artery stenting with embolic protection, left atrial appendage closure, along with rarely used and likely to be abandoned intracranial stenting.

In contrast to causes-oriented therapies used in stroke prevention, therapeutic modalities employed in the emergent management of acute stroke are focused almost exclusively on patients’ cardiopulmonary and hemodynamic support and ad hoc containment of dangerous complications and corresponding brain damage associated with stroke.

Among the life-threatening complications that commonly accompany acute cerebral hemorrhage or ischemia are cerebral edema; hydrocephalus; brain stem compression; vasospasm and pulmonary embolism.

Management of the aforementioned acute complications relies on a few proven treatment regimens, including (but not limited to):

  • medical therapy and catheter-based ventricular drainage of cerebrospinal fluid to control intracerebral pressure in patients at risk of edema, hydrocephalus or brain stem compression;
  • hypertensive hypervolemic hemodilution (or “triple-H” therapy) to treat ischemic neurological deficit from vasospasm following subarachnoid hemorrhage;
  • subcutaneous anticoagulation (with heparins or heparinoids) for prophylaxis of pulmonary embolism (which accounts for approximately 10% of deaths following stroke); and
  • elective hypothermia for temporary salvaging brain cells from necrosis due to hemorrhagic trauma or acute ischemia (although the latter technique has not been proven efficacious in clinical trials and was not endorsed in the latest, 2007 versions of the AHA hemorrhagic and ischemic stroke guidelines).

The currently available curative treatment options for acute stroke are limited to intravenous t-PA therapy (which has about 30% efficacy and is indicated for a very narrow cohort of eligible ischemic stroke patients only), investigational intra-arterial thrombolytic therapy, transcatheter cerebral thrombectomy (in patients who did not qualify for or failed t-PA therapy), and emergency craniotomy-based or endoscopic removal of stroke-related hematoma (which carries a 50% to 80% risk of mortality and is reserved for rapidly deteriorating young patients with large lobar hemorrhages).

Screen Shot 2015-10-04 at 3.11.46 PM
Source Report #C310

The rehabilitation phase of stroke management relies on general physiotherapeutic techniques commonly used in patients with various physical and neurological disabilities. Prophylactics of recurrent cerebrovascular events in stroke survivors employs medical and interventional regimens referred to in the overview of primary and secondary stroke prevention.

At right are the key metrics in the management of acute stroke in the U.S., Western Europe, Asia/Pacific and the rest of the world, as detailed in the MedMarket Diligence report #C310.

Procedures in the management of acute stroke are detailed in the MedMarket Diligence report #C310, with current/forecast procedure volumes for carotid artery stenting, embolization of cerebral aneurysm & AVM, left atrial appendage closure, and cerebral thrombectomy.

Screen Shot 2015-10-04 at 3.20.41 PM

Source Report #C310

 

 

Report: Worldwide Wound Management, Forecast to 2024

Pending Report Announcement

Worldwide Wound Management, Forecast to 2024:
Established and Emerging Products, Technologies and Markets
in the Americas, Europe, Asia/Pacific and Rest of World
· 350 pages · 200 Exhibits · 75 Company Profiles · Report #S251 · November/December 2015
(Click for full report description)

Price: $4,250 (print or PDF; add $200 for both).
Pre-publication $1,000 discount.
Site/Global License also available.

Order online or send us your order form.

This report will detail the complete range of products and technologies used in wound management and wound care, from dressings, bandages, hydrogels, tissue engineered products, physical treatments and others. The report will detail current clinical and technology developments in the worldwide market providing a current assessment of products in development and on the market; market size and forecast; competitor market shares; 75-100 competitor profiles; and an assessment of the market opportunity for current and hopeful competitors.

The report will provide full year (actual) 2014 market size and share data, with forecast market data to 2024, for the Americas (with detail for U.S., Rest of North America and Latin America), Europe (with detail for United Kingdom, Germany, France, Spain, Italy, and Rest of Europe), Asia/Pacific (with detail for Japan, Korea, and Rest of Asia/Pacific) and Rest of World.

This report will detail the current and projected market for wound management products, including dressings, closure devices, debridement, pharmacological products, tissue engineered products and others. Emphasis will be placed on advanced and leading edge developments (i.e., those approaching wound management from novel perspective) such as growth factors, stem cells, gene therapy and other approaches, while baseline data (current and forecast market size and current competitor market shares per country) will be provided for established segments — multiple dressings types (film, foam, alginate, antibacterial, non-adherent), hydrogels, hydrocolloids, pharmaceuticals, and physical treatments. The report will detail the clinical and technology developments underlying the clinical practice and market development in wound care market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor data are presented for the U.S., rest of North America, Latin America, leading western European countries (specifically, United Kingdom, Germany, France, Italy, Spain), rest of Europe, Japan, Korea, rest of Asia/Pacific, and the Rest of World category. The report’s company profiles will assess leading and key emerging companies regarding current/projected products, technologies and positions in the advanced wound care market.

TABLE OF CONTENTS
EXECUTiVE SUMMARY
SECTION 1: INDUSTRY BACKGROUND
1.1. Industry Structure
1.2. A Complex Industry
1.3. Historical Perspective and Technology Breakthroughs
1.4. Wound Management Trends
1.4.1. Surgical Wounds
1.4.2. Traumatic Wounds
1.4.3. Burns
1.4.4. Chronic Wounds
1.5. Market Dynamics
SECTION 2: CLINICAL BACKGROUND AND CASELOAD
2.1. Background
2.2. Skin Anatomy: A Summary
2.3. Types of Wounds
2.3.1. Classification
2.3.1.1. Wagner Classification System
2.3.1.2. By Severity
2.3.1.3. By Morphology
2.3.1.4. By Etiology
2.3.1.5. Color Classification
2.3.2. Surgical Wounds
2.3.3. Traumatic Wounds
2.3.4. Burns
2.3.4.1. Debridement
2.3.4.2. Grafting
2.3.5. Pressure Ulcers
2.3.5.1. Ulcer Classification
2.3.5.2. Hospital-Acquired Ulcers
2.3.6. Venous Ulcers
2.3.7. Arterial Ulcers
2.3.8. Diabetic Ulcers
2.3.8.1. Prevalence
2.3.8.2. Stages of Diabetic Ulcers
2.3.8.3. Treatment
2.3.8.4. Amputations
2.3.8.5. Novel treatment for Diabetic Foot Ulcers
2.4. Wound Healing Physiology
2.4.1. Inflammatory Phase
2.4.2. Proliferative Phase
2.4.3. Angiogenesis
2.4.4. Maturation Phase
2.5. Factors Affecting Wound Healing
2.5.1. Extrinsic Factors
2.5.1.1. Mechanical Stress
2.5.1.2. Debris
2.5.1.3. Temperature
2.5.1.4. Desiccation and Maceration
2.5.1.5. Infection
2.5.1.6. Chemical Stress
2.5.1.7. Medication
2.5.1.8. Other Extrinsic Factors
2.5.2. Intrinsic Factors
2.5.2.1. Health Status
2.5.2.1.1. Acquired Immune Deficiency Syndrome
2.5.2.2. Age Factors
2.5.2.3. Body Build
2.5.2.4. Nutritional Status
2.6. Major Treatment Categories and Regimens
2.7. Incidence of Treatments, Growth Rates and Trends
SECTION 3: PRODUCTS, TECHNOLOGIES AND MARKETS
3.1. Background
3.2. Traditional Wound Care Products
3.2.1. Adhesive Dressings
3.2.1.1. Market and Competitive Activity
3.2.2. Gauze
3.2.2.1. Market and Competitive Activity
3.2.3. Non-Adherent Dressings
3.2.3.1. Market and Competitive Activity
3.3. Interactive Wound Healing Products
3.3.1. Film Dressings
3.3.1.1. Overview
3.3.1.2. Leading Products and Other Product Examples
3.3.1.3. Market and Competitive Activity
3.3.2. Foam Dressings
3.3.2.1. Overview
3.3.2.2. Leading Products and Other Product Examples
3.3.2.3. Market and Competitive Activity
3.3.3. Hydrogels
3.3.3.1. Overview
3.3.3.2. Leading Products and Other Product Examples
3.3.3.3. Market and Competitive Activity
3.4. Bioactive Wound Healing Products
3.4.1. Hydrocolloids
3.4.1.1. Overview
3.4.1.2. Leading Products and Other Product Examples
3.4.1.3. Market and Competitive Activity
3.4.2. Alginate Dressings
3.4.2.1. Overview
3.4.2.2. Market and Competitive Activity
3.4.2.3. Leading Products and Other Product Examples
3.4.3. Antimicrobial Dressings
3.4.3.1. Overview
3.4.3.2. Leading Products and Other Product Examples
3.4.3.3. Market and Competitive Activity
3.5. Biologics
3.5.1. Overview
3.5.2. Bioengineered Skin & Skin Substitutes
3.5.3. Market and Competitive Activity
3.6. Wound Care Devices
3.6.1. Negative Pressure Devices
3.6.1.1. Overview
3.6.1.2. Leading Products and Other Product Examples
3.6.1.3. Market and Competitive Activity
3.6.2. Ultrasound Devices
3.6.2.1. Overview
3.6.2.2. Leading Products and Other Product Examples
3.6.2.3. Market and Competitive Activity
3.6.3. Electrical Stimulation Devices
3.6.3.1. Overview
3.6.3.2. Pulsed Electromagnetic Therapy (PEMF)
3.7. Emerging Wound Therapy Technologies
3.7.1. Growth Factors: Introduction
3.7.2. Growth Factor Nomenclature
3.7.3. Developments in Growth Factors
3.7.4. Market and Competitive Activity
SECTION 4: COUNTRY MARKET FORECAST 2014-2024
4.1. Global Overview
4.2. Market Estimates
4.2.1. Global Market for Traditional Adhesive Dressings
4.2.2. Global Market for Traditional Gauze Dressings
4.2.3. Global Market for Non-Adherent Dressings
4.2.4. Global Market for Film Dressings
4.2.5. Global Market for Foam Dressings
4.2.6. Global Market for Hydrogel Dressings
4.2.7. Global Market for Hydrocolloid Dressings
4.2.8. Global Market for Alginate Dressings
4.2.9. Global Market for Antimicrobial Dressings
4.2.10. Global Market for Negative Pressure Wound Therapy
4.2.11. Global Market for Bioengineered Skin & Skin Substitutes
4.2.12. Global Market for Wound Care Growth Factors
4.3. Market Potential
4.4. Leading Companies in the Wound Management Market
4.5. Competitor Market Shares by Product
4.5.1. Market Shares by Country for Traditional Adhesive Dressings
4.5.1.1. United States
4.5.1.2. Rest of North America
4.5.1.3. Latin America
4.5.1.4. EU
4.5.1.4.1. United Kingdom
4.5.1.4.2. Germany
4.5.1.4.3. France
4.5.1.4.4. Italy
4.5.1.4.5. Spain
4.5.1.4.6. Rest of EU
4.5.1.5. Asia Pacific
4.5.1.5.1. Japan
4.5.1.5.2. Korea
4.5.1.5.3. Rest of Asia Pacific
4.5.1.6. Rest of World
4.5.2. Market Shares by Country for Traditional Gauze Dressings
4.5.2.1. United States
4.5.2.2. Rest of North America
4.5.2.3. Latin America
4.5.2.4. EU
4.5.2.4.1. United Kingdom
4.5.2.4.2. Germany
4.5.2.4.3. France
4.5.2.4.4. Italy
4.5.2.4.5. Spain
4.5.2.4.6. Rest of EU
4.5.2.5. Asia Pacific
4.5.2.5.1. Japan
4.5.2.5.2. Korea
4.5.2.5.3. Rest of Asia Pacific
4.5.2.6. Rest of World
4.5.3. Market Shares by Country for Non-Adherent Dressings
4.5.3.1. United States
4.5.3.2. Rest of North America
4.5.3.3. Latin America
4.5.3.4. EU
4.5.3.4.1. United Kingdom
4.5.3.4.2. Germany
4.5.3.4.3. France
4.5.3.4.4. Italy
4.5.3.4.5. Spain
4.5.3.4.6. Rest of EU
4.5.3.5. Asia Pacific
4.5.3.5.1. Japan
4.5.3.5.2. Korea
4.5.3.5.3. Rest of Asia Pacific
4.5.3.6. Rest of World
4.5.4. Market Shares by Country for Film Dressings
4.5.4.1. United States
4.5.4.2. Rest of North America
4.5.4.3. Latin America
4.5.4.4. EU
4.5.4.4.1. United Kingdom
4.5.4.4.2. Germany
4.5.4.4.3. France
4.5.4.4.4. Italy
4.5.4.4.5. Spain
4.5.4.4.6. Rest of EU
4.5.4.5. Asia Pacific
4.5.4.5.1. Japan
4.5.4.5.2. Korea
4.5.4.5.3. Rest of Asia Pacific
4.5.4.6. Rest of World
4.5.5. Market Shares by Country for Foam Dressings
4.5.5.1. United States
4.5.5.2. Rest of North America
4.5.5.3. Latin America
4.5.5.4. EU
4.5.5.4.1. United Kingdom
4.5.5.4.2. Germany
4.5.5.4.3. France
4.5.5.4.4. Italy
4.5.5.4.5. Spain
4.5.5.4.6. Rest of EU
4.5.5.5. Asia Pacific
4.5.5.5.1. Japan
4.5.5.5.2. Korea
4.5.5.5.3. Rest of Asia Pacific
4.5.5.6. Rest of World
4.5.6. Market Shares by Country for Hydrogel Dressings
4.5.6.1. United States
4.5.6.2. Rest of North America
4.5.6.3. Latin America
4.5.6.4. EU
4.5.6.4.1. United Kingdom
4.5.6.4.2. Germany
4.5.6.4.3. France
4.5.6.4.4. Italy
4.5.6.4.5. Spain
4.5.6.4.6. Rest of EU
4.5.6.5. Asia Pacific
4.5.6.5.1. Japan
4.5.6.5.2. Korea
4.5.6.5.3. Rest of Asia Pacific
4.5.6.6. Rest of World
4.5.7. Market Shares by Country for Hydrocolloid Dressings
4.5.7.1. United States
4.5.7.2. Rest of North America
4.5.7.3. Latin America
4.5.7.4. EU
4.5.7.4.1. United Kingdom
4.5.7.4.2. Germany
4.5.7.4.3. France
4.5.7.4.4. Italy
4.5.7.4.5. Spain
4.5.7.4.6. Rest of EU
4.5.7.5. Asia Pacific
4.5.7.5.1. Japan
4.5.7.5.2. Korea
4.5.7.5.3. Rest of Asia Pacific
4.5.7.6. Rest of World
4.5.8. Market Shares by Country for Alginate Dressings
4.5.8.1. United States
4.5.8.2. Rest of North America
4.5.8.3. Latin America
4.5.8.4. EU
4.5.8.4.1. United Kingdom
4.5.8.4.2. Germany
4.5.8.4.3. France
4.5.8.4.4. Italy
4.5.8.4.5. Spain
4.5.8.4.6. Rest of EU
4.5.8.5. Asia Pacific
4.5.8.5.1. Japan
4.5.8.5.2. Korea
4.5.8.5.3. Rest of Asia Pacific
4.5.8.6. Rest of World
4.5.9. Market Shares by Country for Antimicrobial Dressings
4.5.9.1. United States
4.5.9.2. Rest of North America
4.5.9.3. Latin America
4.5.9.4. EU
4.5.9.4.1. United Kingdom
4.5.9.4.2. Germany
4.5.9.4.3. France
4.5.9.4.4. Italy
4.5.9.4.5. Spain
4.5.9.4.6. Rest of EU
4.5.9.5. Asia Pacific
4.5.9.5.1. Japan
4.5.9.5.2. Korea
4.5.9.5.3. Rest of Asia Pacific
4.5.9.6. Rest of World
4.5.10. Market Shares by Country for Negative Pressure Wound Therapy
4.5.10.1. United States
4.5.10.2. Rest of North America
4.5.10.3. Latin America
4.5.10.4. EU
4.5.10.4.1. United Kingdom
4.5.10.4.2. Germany
4.5.10.4.3. France
4.5.10.4.4. Italy
4.5.10.4.5. Spain
4.5.10.4.6. Rest of EU
4.5.10.5. Asia Pacific
4.5.10.5.1. Japan
4.5.10.5.2. Korea
4.5.10.5.3. Rest of Asia Pacific
4.5.10.6. Rest of World
4.5.11. Market Shares by Country for Bioengineered Skin & Skin Substitutes
4.5.11.1. United States
4.5.11.2. Rest of North America
4.5.11.3. Latin America
4.5.11.4. EU
4.5.11.4.1. United Kingdom
4.5.11.4.2. Germany
4.5.11.4.3. France
4.5.11.4.4. Italy
4.5.11.4.5. Spain
4.5.11.4.6. Rest of EU
4.5.11.5. Asia Pacific
4.5.11.5.1. Japan
4.5.11.5.2. Korea
4.5.11.5.3. Rest of Asia Pacific
4.5.11.6. Rest of World
4.5.12. Market Shares by Country for Wound Care Growth Factors
4.5.12.1. United States
4.5.12.2. Rest of North America
4.5.12.3. Latin America
4.5.12.4. EU
4.5.12.4.1. United Kingdom
4.5.12.4.2. Germany
4.5.12.4.3. France
4.5.12.4.4. Italy
4.5.12.4.5. Spain
4.5.12.4.6. Rest of EU
4.5.12.5. Asia Pacific
4.5.12.5.1. Japan
4.5.12.5.2. Korea
4.5.12.5.3. Rest of Asia Pacific
4.5.12.6. Rest of World
4.6. Regional and Country Market Sizes
4.7. Americas
4.7.1. United States
4.7.1.1. USA Market for Traditional Adhesive Dressings
4.7.1.2. USA Market for Traditional Gauze Dressings
4.7.1.3. USA Market for Non-Adherent Dressings
4.7.1.4. USA Market for Film Dressings
4.7.1.5. USA Market for Foam Dressings
4.7.1.6. USA Market for Hydrogel Dressings
4.7.1.7. USA Market for Hydrocolloid Dressings
4.7.1.8. USA Market for Alginate Dressings
4.7.1.9. USA Market for Antimicrobial Dressings
4.7.1.10. USA Market for Negative Pressure Wound Therapy
4.7.1.11. USA Market for Bioengineered Skin & Skin Substitutes
4.7.1.12. USA Market for Wound Care Growth Factors
4.7.2. Rest of North America
4.7.2.1. Rest of North America Market for Traditional Adhesive Dressings
4.7.2.2. Rest of North America Market for Traditional Gauze Dressings
4.7.2.3. Rest of North America Market for Non-Adherent Dressings
4.7.2.4. Rest of North America Market for Film Dressings
4.7.2.5. Rest of North America Market for Foam Dressings
4.7.2.6. Rest of North America Market for Hydrogel Dressings
4.7.2.7. Rest of North America Market for Hydrocolloid Dressings
4.7.2.8. Rest of North America Market for Alginate Dressings
4.7.2.9. Rest of North America Market for Antimicrobial Dressings
4.7.2.10. Rest of North America Market for Negative Pressure Wound Therapy
4.7.2.11. Rest of North America Market for Bioengineered Skin and Skin Substitutes
4.7.2.12. Rest of North America Market for Wound Care Growth Factors
4.7.3. Latin America
4.7.3.1. Latin America Market for Traditional Adhesive Dressings
4.7.3.2. Latin America Market for Traditional Gauze Dressings
4.7.3.3. Latin America Market for Non-Adherent Dressings
4.7.3.4. Latin America Market for Film Dressings
4.7.3.5. Latin America Market for Foam Dressings
4.7.3.6. Latin America Market for Hydrogel Dressings
4.7.3.7. Latin America Market for Hydrocolloid Dressings
4.7.3.8. Latin America Market for Alginate Dressings
4.7.3.9. Latin America Market for Antimicrobial Dressings
4.7.3.10. Latin America Market for Negative Pressure Wound Therapy Devices
4.7.3.11. Latin America Market for Bioengineered Skin and Skin Substitutes
4.7.3.12. Latin America Market for Wound Care Growth Factors
4.8. European Union
4.8.1. United Kingdom
4.8.1.1. UK Market for Traditional Adhesive Dressings
4.8.1.2. UK Market for Traditional Gauze Dressings
4.8.1.3. UK Market for Non-Adherent Dressings
4.8.1.4. UK Market for Film Dressings
4.8.1.5. UK Market for Foam Dressings
4.8.1.6. UK Market for Hydrogel Dressings
4.8.1.7. UK Market for Hydrocolloid Dressings
4.8.1.8. UK Market for Alginate Dressings
4.8.1.9. UK Market for Antimicrobial Dressings
4.8.1.10. UK Market for Negative Pressure Wound Therapy Devices
4.8.1.11. UK Market Bioengineered Skin and Skin Substitutes
4.8.1.12. United Kingdom Market for Wound Care Growth Factors
4.8.2. Germany
4.8.2.1. Germany Market for Traditional Adhesive Dressings
4.8.2.2. Germany Market for Traditional Gauze Dressings
4.8.2.3. Germany Market for Non-Adherent Dressings
4.8.2.4. Germany Market for Film Dressings
4.8.2.5. Germany Market for Foam Dressings
4.8.2.6. Germany Market for Hydrogel Dressings
4.8.2.7. Germany Market for Hydrocolloid Dressings
4.8.2.8. Germany Market for Alginate Dressings
4.8.2.9. Germany Market for Antimicrobial Dressings
4.8.2.10. Germany Market for Negative Pressure Wound Therapy Devices
4.8.2.11. Germany Market for Bioengineered Skin and Skin Substitutes
4.8.2.12. Germany Market for Wound Care Growth Factors
4.8.3. France
4.8.3.1. France Market for Traditional Adhesive Dressings
4.8.3.2. France Market for Traditional Gauze Dressings
4.8.3.3. France Market for Non-Adherent Dressings
4.8.3.4. France Market for Film Dressings
4.8.3.5. France Market for Foam Dressings
4.8.3.6. France Market for Hydrogel Dressings
4.8.3.7. France Market for Hydrocolloid Dressings
4.8.3.8. France Market for Alginate Dressings
4.8.3.9. France Market for Antimicrobial Dressings
4.8.3.10. France Market for Negative Pressure Wound Therapy Devices
4.8.3.11. France Market for Bioengineered Skin and Skin Substitutes
4.8.3.12. France Market for Wound Care Growth Factors
4.8.4. Italy
4.8.4.1. Italy Market for Traditional Adhesive Dressings
4.8.4.2. Italy Market for Traditional Gauze Dressings
4.8.4.3. Italy Market for Non-Adherent Dressings
4.8.4.4. Italy Market for Film Dressings
4.8.4.5. Italy Market for Foam Dressings
4.8.4.6. Italy Market for Hydrogel Dressings
4.8.4.7. Italy Market for Hydrocolloid Dressings
4.8.4.8. Italy Market for Alginate Dressings
4.8.4.9. Italy Market for Antimicrobial Dressings
4.8.4.10. Italy Market for Negative Pressure Wound Therapy Devices
4.8.4.11. Italy Market for Bioengineered Skin and Skin Substitutes
4.8.4.12. Italy Market for Wound Care Growth Factors
4.8.5. Spain
4.8.5.1. Spain Market for Traditional Adhesive Dressings
4.8.5.2. Spain Market for Traditional Gauze Dressings
4.8.5.3. Spain Market for Non-Adherent Dressings
4.8.5.4. Spain Market for Film Dressings
4.8.5.5. Spain Market for Foam Dressings
4.8.5.6. Spain Market for Hydrogel Dressings
4.8.5.7. Spain Market for Hydrocolloid Dressings
4.8.5.8. Spain Market for Alginate Dressings
4.8.5.9. Spain Market for Antimicrobial Dressings
4.8.5.10. Spain Market for Negative Pressure Wound Therapy Devices
4.8.5.11. Spain Market for Bioengineered Skin and Skin Substitutes
4.8.5.12. Spain Market for Wound Care Growth Factors
4.8.6. Rest of Europe
4.8.6.1. Rest of Europe Market for Traditional Adhesive Dressings
4.8.6.2. Rest of Europe Market for Traditional Gauze Dressings
4.8.6.3. Rest of Europe Market for Non-Adherent Dressings
4.8.6.4. Rest of Europe Market for Film Dressings
4.8.6.5. Rest of Europe Market for Foam Dressings
4.8.6.6. Rest of Europe Market for Hydrogel Dressings
4.8.6.7. Rest of Europe Market for Hydrocolloid Dressings
4.8.6.8. Rest of Europe Market for Alginate Dressings
4.8.6.9. Rest of Europe Market for Antimicrobial Dressings
4.8.6.10. Rest of Europe Market for Negative Pressure Wound Therapy Devices
4.8.6.11. Rest of Europe Market for Bioengineered Skin and Skin Substitutes
4.8.6.12. Rest of Europe Market for Wound Care Growth Factors
4.9. Asia/Pacific
4.9.1. Japan
4.9.1.1. Japan Market for Traditional Adhesive Dressings
4.9.1.2. Japan Market for Traditional Gauze Dressings
4.9.1.3. Japan Market for Non-Adherent Dressings
4.9.1.4. Japan Market for Film Dressings
4.9.1.5. Japan Market for Foam Dressings
4.9.1.6. Japan Market for Hydrogel Dressings
4.9.1.7. Japan Market for Hydrocolloid Dressings
4.9.1.8. Japan Market for Alginate Dressings
4.9.1.9. Japan Market for Antimicrobial Dressings
4.9.1.10. Japan Market for Negative Pressure Wound Therapy Devices
4.9.1.11. Japan Market for Bioengineered Skin and Skin Substitutes
4.9.1.12. Japan Market for Wound Care Growth Factors
4.9.2. Korea
4.9.2.1. Korea Market for Traditional Adhesive Dressings
4.9.2.2. Korea Market for Traditional Gauze Dressings
4.9.2.3. Korea Market for Non-Adherent Dressings
4.9.2.4. Korea Market for Film Dressings
4.9.2.5. Korea Market for Foam Dressings
4.9.2.6. Korea Market for Hydrogel Dressings
4.9.2.7. Korea Market for Hydrocolloid Dressings
4.9.2.8. Korea Market for Alginate Dressings
4.9.2.9. Korea Market for Antimicrobial Dressings
4.9.2.10. Korea Market for Negative Pressure Wound Therapy Devices
4.9.2.11. Korea Market for Bioengineered Skin and Skin Substitutes
4.9.2.12. Korea Market for Wound Care Growth Factors
4.9.3. Rest of Asia/Pacific
4.9.3.1. Rest of Asia/Pacific Market for Traditional Adhesive Dressings
4.9.3.2. Rest of Asia/Pacific Market for Traditional Gauze Dressings
4.9.3.3. Rest of Asia/Pacific Market for Non-Adherent Dressings
4.9.3.4. Rest of Asia/Pacific Market for Film Dressings
4.9.3.5. Rest of Asia/Pacific Market for Foam Dressings
4.9.3.6. Rest of Asia/Pacific Market for Hydrogel Dressings
4.9.3.7. Rest of Asia/Pacific Market for Hydrocolloid Dressings
4.9.3.8. Rest of Asia/Pacific Market for Alginate Dressings
4.9.3.9. Rest of Asia/Pacific Market for Antimicrobial Dressings
4.9.3.10. Rest of Asia/Pacific Market for Negative Pressure Wound Therapy Devices
4.9.3.11. Rest of Asia/Pacific Market for Bioengineered Skin and Skin Substitutes
4.9.3.12. Rest of Asia/Pacific Market for Wound Care Growth Factors
4.9.4. Rest of World
4.9.4.1. Rest of World Market for Traditional Adhesive Dressings
4.9.4.2. Rest of World Market for Traditional Gauze Dressings
4.9.4.3. Rest of World Market for Non-Adherent Dressings
4.9.4.4. Rest of World Market for Film Dressings
4.9.4.5. Rest of World Market for Foam Dressings
4.9.4.6. Rest of World Market for Hydrogel Dressings
4.9.4.7. Rest of World Market for Hydrocolloid Dressings
4.9.4.8. Rest of World Market for Alginate Dressings
4.9.4.9. Rest of World Market for Antimicrobial Dressings
4.9.4.10. Rest of World Market for Negative Pressure Wound Therapy Devices
4.9.4.11. Rest of World Market for Bioengineered Skin and Skin Substitutes
4.9.4.12. Rest of World Market for Wound Care Growth Factors
SECTION 5: COMPANY PROFILES (preliminary, subject to change)
5.1. 3M Health Care
5.2. ACell
5.3. AcryMed Inc.
5.4. Agennix Incorporated
5.5. AGT Sciences Ltd
5.6. Altrika Ltd
5.7. Anika Therapeutics
5.8. Argentum Medical
5.9. Avita Medical
5.10. B. Braun Melsungen AG
5.11. Biopharm GmbH
5.12. Biotime, Inc.
5.13. BSN Medical GmbH
5.14. Cardium Therapeutics
5.15. CliniMed Limited
5.16. Coloplast Group
5.17. Covalon Technologies, Ltd.
5.18. ConvaTec Inc.
5.19. Cook Biotech, Inc.
5.20. Covidien
5.21. Cytogenix
5.22. Cytomedix
5.23. Derma Sciences, Inc.
5.24. DeRoyal Industries Inc.
5.25. Diapulse Corporation of America
5.26. Eqalix, Inc.
5.27. Euroderm AG
5.28. Gentell Inc
5.29. Geritrex Corp.
5.30. Hartmann Group
5.31. Hollister Incorporated
5.32. Imbed Biosciences, Inc.
5.33. Integra LifeSciences, Inc.
5.34. Kendall (Covidien)
5.35. Kinetic Concepts, Inc. (Acelity)
5.36. Kuros Biosurgery AG
5.37. Laboratoires Urgo
5.38. LifeCell Corporation (Acelity)
5.39. Lohmann & Rauscher International GmbH and Co. KG
5.40. Macrocure
5.41. Medline Industries
5.42. Microban International Ltd.
5.43. MicroVas Technologies, Inc
5.44. Mölnlycke Health Care AB
5.45. NovaBay Pharmaceuticals
5.46. Oculus Innovative Sciences
5.47. Organogenesis Inc
5.48. Osiris Therapeutics
5.49. Perry Baromedical
5.50. RXi Pharmaceuticals
5.51. SafeBlood Technologies
5.52. Sanofi Biosurgery (formerly Genzyme Biosurgery)
5.53. SANUWAVE Health, Inc.
5.54. Shire Regenerative Medicine
5.55. Smith & Nephew plc
5.56. Soluble Solutions, LLC
5.57. Spiracur, Inc.
5.58. Systagenix, Inc. (Acelity)
5.59. TEI Biosciences
5.60. Tissue Regeneration Technologies, LLC
5.61. UDL Laboratories
5.62. Uluru, Inc.
5.63. Vomaris Innovations, Inc.

APPENDIX: COMPANY DIRECTORY


Worldwide Wound Management, Forecast to 2024:
Established and Emerging Products, Technologies and Markets
in the Americas, Europe, Asia/Pacific and Rest of World
· 350 pages · 200 Exhibits · 75 Company Profiles · Report #S251 · October 2015
(Click for full report description)

Price: $4,250 (print or PDF; add $200 for both).
Pre-publication $1,000 discount.
Site/Global License also available.

Order online or send us your order form.

 

Neurointerventional Treatments for Acute Stroke

Stroke is a life-threatening medical condition characterized by a sudden catastrophic breakdown in the brain-supporting cerebrovascular system and blood supply, which, in many instances, is followed by an irreversible injury to the brain cells and severe neurological impairment or death.

Notwithstanding the remarkable progress in medical science and technology and associated improvements in clinical practices, stroke continues to constitute the major public health problem in the U.S. and overseas. According to the World Health Organization (WHO), OECD, and governments’ data, approximately 14 million to 16 million people worldwide  suffered a stroke in 2014, of which roughly 75% of the cases (10.5 – 12.0 million) represented first attacks and 25% (or 3.5 to 4.0 million cases) were qualified as recurrent attacks. Based on the same sources, about 5 million acute stroke episodes result in death within one year globally, which makes it the third most common cause of death, behind diseases of the heart and cancer.

Stroke is also a leading cause of serious and lasting disability and long-term institutionalized care.

Acute stroke – also known as “cerebrovascular accident” – represents a catastrophic manifestation of accumulated circulatory disorders that affect the vasculature of the brain. The two major subdivision of stroke are ischemia or lack of blood and oxygen supply typically resulting from occlusion of cerebral arteries, and hemorrhage or leakage of blood outside the normal cerebral vessel conduit. Both types of stroke cause necrosis of certain groups of brain cells, which leads to irreversible impairment of various neurological functions in about 22% to 25% of patients and death within one year in another 20% to 25% of stroke caseloads.

Acute stroke is managed by a broad scope of prophylactic, palliative and curative treatment regimens that are typically employed in some combinations during the preventive, acute and rehabilitation phases of stroke-related care delivery.

Treatments for acute stroke are the subject of the MedMarket Diligence report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019” (see details)

Although sales are low now, one of the fast(er) growing areas in the neurointerventional management of stroke is technologies to provide closure of the left atrial appendage, a vestige of the embryonic left atrium which, for patients with atrial fibrillation, can result in the formation of blood clots in the relatively stagnant pooled blood in the appendage.

Currently, only the Watchman LAA Closure System is approved in the U.S. for left atrial appendage closure, but sales are now projected to grow at 13% annually through 2019. Consequently, the make-up of the market will change considerably from 2014 to 2019:

Screen Shot 2015-09-30 at 6.32.21 PM Screen Shot 2015-09-30 at 6.32.40 PM

Source: MedMarket Diligence, LLC; Report #C310 (published September 2015).